Literature DB >> 8075583

Apoptotic cell death during treatment of leukemias.

X Li1, J Gong, E Feldman, K Seiter, F Traganos, Z Darzynkiewicz.   

Abstract

The apoptosis-associated DNA strand breaks were detected in situ, in individual leukemic cells in peripheral blood and bone marrow of over 110 patients with different types of leukemia (ALL, AML, CML in blastic crisis, APL), prior to and during routine chemotherapy. The DNA strand breaks were labeled with digoxigenin- or biotin-conjugated dUTP in the reaction catalyzed by exogenous terminal deoxynucleotidyl transferase, and the cells, counterstained for DNA, were analyzed by bivariate flow cytometry. The proportion of cells with DNA strand breaks prior to therapy, most likely reflecting spontaneous apoptosis, varied from 0.1 to 16%, but in the large majority of cases was below 3%. Administration of drugs of different classes, which included DNA topoisomerase I (Topotecan) and II (mitoxantrone, VP-16) inhibitors, antimetabolite (ara-C) or microtubule poison (Taxol), all triggered the appearance of cells with extensive DNA breakage, typical of apoptosis, to up to 80%. The peak of the response, measured as maximal percent of cells with DNA strand breaks, which varied between individual patients by as much as factor 10, was generally seen between 8 to 24 h after the initial administration of DNA topoisomerase inhibitors, and somewhat later (48-72 h) during the response to Taxol or ara-C. Thus, the data show that the response to treatment with a variety of drugs, in terms of induction of apoptosis, can be conveniently measured by the present method. The prognostic value of the apoptotic index, before, as well as during treatment, is being estimated for each type of leukemia, in the ongoing prospective studies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8075583     DOI: 10.3109/10428199409052678

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.

Authors:  Matthew J Martin; Nataliya Melnyk; Michelle Pollard; Mary Bowden; Hon Leong; Thomas J Podor; Martin Gleave; Poul H B Sorensen
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

2.  Detection of DNA strand breaks in apoptotic cells by flow- and image-cytometry.

Authors:  Zbigniew Darzynkiewicz; Hong Zhao
Journal:  Methods Mol Biol       Date:  2011

3.  Degradation of apoptotic cells and fragments in HL-60 suspension cultures after induction of apoptosis by camptothecin and ethanol.

Authors:  H Baisch; H Bollmann; S Bornkessel
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

4.  Cytostatic and apoptotic effects of paclitaxel in human ovarian tumors.

Authors:  N J Millenbaugh; Y Gan; J L Au
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

5.  Detection of DNA strand breaks by flow and laser scanning cytometry in studies of apoptosis and cell proliferation (DNA replication).

Authors:  Zbigniew Darzynkiewicz; Xuan Huang; Masaki Okafuji
Journal:  Methods Mol Biol       Date:  2006

6.  Effects of serum of Kawasaki disease on PDGF expression in monocytes and on endothelial cell apoptosis.

Authors:  H Wang; H Wang; P Cheng
Journal:  J Tongji Med Univ       Date:  1999

Review 7.  Apoptosis in glioma cells: review and analysis of techniques used for study with focus on the laser scanning cytometer.

Authors:  Bardia Amirlak; William T Couldwell
Journal:  J Neurooncol       Date:  2003-06       Impact factor: 4.130

Review 8.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

9.  DNA damage response as a biomarker in treatment of leukemias.

Authors:  H Dorota Halicka; M Fevzi Ozkaynak; Oya Levendoglu-Tugal; Claudio Sandoval; Karen Seiter; Malgorzata Kajstura; Frank Traganos; Somasunadaram Jayabose; Zbigniew Darzynkiewicz
Journal:  Cell Cycle       Date:  2009-06-30       Impact factor: 4.534

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.